Literature DB >> 31992376

Prescription opioid misuse motive latent classes: outcomes from a nationally representative US sample.

Ty S Schepis1, A S De Nadai1, J A Ford2, S E McCabe3,4,5,6.   

Abstract

AIMS: Prescription opioid misuse (POM) contributes to a larger opioid crisis in the US and Canada, with over 17 000 US POM-related overdose deaths in 2017. Our aims were to (1) identify specific profiles of respondents based on POM motives using the US National Survey on Drug Use and Health (NSDUH) and (2) compare profile respondents on sociodemographics, substance use and mental and physical health outcomes.
METHODS: Analyses included 2017-18 NSDUH respondents with data on POM motives (n = 4810). POM was defined as prescription opioid use in a way not intended by the prescriber, including use without a prescription, in larger amounts or more frequently. Nine POM motives for the most recent episode were assessed, including 'to relieve physical pain' and 'to get high'. Latent classes, based on POM motives, were estimated. Classes were compared on sociodemographics, substance use and physical and mental health outcomes.
RESULTS: Eight latent classes were identified (in order of prevalence): pain relief only, relax-pain relief, sleep-pain relief, multi-motive, high, experimenter, emotional coping and dependent/hooked. Compared to the pain relief only group, the high and multi-motive classes had higher odds of all substance use outcomes, with the dependent/hooked class having higher odds on all but one outcome. Six of the eight classes had higher odds of past-year mental health treatment and suicidal ideation than the pain relief only class.
CONCLUSIONS: Screening for pain, pain conditions, problematic substance use and psychopathology are recommended in those with any POM. While those in the dependent/hooked, multi-motive and emotional coping classes are most likely to have prescription opioid use disorder (OUD), screening for OUD symptoms in all individuals with POM is also warranted.

Entities:  

Keywords:  Latent class analysis; misuse; motive; prescription opioid; substance use disorder

Year:  2020        PMID: 31992376     DOI: 10.1017/S2045796020000037

Source DB:  PubMed          Journal:  Epidemiol Psychiatr Sci        ISSN: 2045-7960            Impact factor:   6.892


  7 in total

1.  Motivations for Prescription Drug Misuse Related to Mental Health Problems in Adults.

Authors:  Tess K Drazdowski; Marya Schulte; Kate B Wolitzky-Taylor; Holle Schaper; Jason E Chapman
Journal:  Subst Use Misuse       Date:  2021-12-14       Impact factor: 2.164

2.  Are Pain and Negative Affect Coping Distinct Motives for Opioid Misuse?

Authors:  R Kathryn McHugh; Alexandra Chase; Catherine D Trinh; Roger D Weiss
Journal:  Subst Use Misuse       Date:  2022-03-08       Impact factor: 2.362

3.  Co-ingestion of prescription drugs and alcohol in US adults aged 50 years or older.

Authors:  Ty S Schepis; Jason A Ford; Sean Esteban McCabe
Journal:  Hum Psychopharmacol       Date:  2021-07-08       Impact factor: 2.130

4.  Poly-prescription drug misuse across the life course: Prevalence and correlates across different adult age cohorts in the U.S.

Authors:  Jason A Ford; Ty S Schepis; Sean Esteban McCabe
Journal:  Int J Drug Policy       Date:  2020-11-20

5.  Associations between adolescent sleep deficiency and prescription opioid misuse in adulthood.

Authors:  Cornelius B Groenewald; Emily F Law; Jennifer A Rabbitts; Tonya M Palermo
Journal:  Sleep       Date:  2021-03-12       Impact factor: 5.849

6.  Substance use patterns and health profiles among US adults who use opioids, methamphetamine, or both, 2015-2018.

Authors:  Riley D Shearer; Benjamin A Howell; Gavin Bart; Tyler N A Winkelman
Journal:  Drug Alcohol Depend       Date:  2020-07-02       Impact factor: 4.492

7.  Negative affect-associated drug refusal self-efficacy, illicit opioid use, and medication use following short-term inpatient opioid withdrawal management.

Authors:  Jumi Hayaki; Micah T Conti; Genie L Bailey; Debra S Herman; Bradley J Anderson; Michael D Stein
Journal:  J Subst Abuse Treat       Date:  2021-01-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.